Risks and Benefits of Rituximab in the Treatment of Hashimoto Encephalopathy in Children: Two Case Reports and a Mini Review

Annemieke Maas, Kees P J Braun, Karin Geleijns, Floor E. Jansen, Annet van Royen-Kerkhof*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Hashimoto encephalopathy is a rare condition, characterized by the association of encephalopathy with a variety of neurological symptoms and autoantibodies to the thyroid gland. Its etiology is unknown, and symptoms are usually treated with immune suppressive therapy, e.g., high doses of corticosteroids. Methods and results: Here, we report the long-term outcome in two steroid-refractory adolescents with Hashimoto encephalopathy who were treated with rituximab, a monoclonal antibody directed against CD20. In addition, we reviewed the literature regarding treatment strategies in Hashimoto encephalopathy. Conclusions: Anti-B-cell therapy can be of value in the treatment of Hashimoto encephalopathy, especially in steroid refractory cases, but side effects due to low levels of immunoglobulins warrant careful monitoring.

Original languageEnglish
Pages (from-to)28-31
Number of pages4
JournalPediatric Neurology
Volume66
DOIs
Publication statusPublished - Jan 2017

Keywords

  • Anti-B-cell therapy
  • Corticosteroid treatment
  • Hashimoto encephalopathy
  • Hypogammaglobulinemia
  • Rituximab
  • Hashimoto encephalopathy
  • hypogammaglobulinemia
  • anti-B-cell therapy
  • corticosteroid treatment
  • rituximab

Fingerprint

Dive into the research topics of 'Risks and Benefits of Rituximab in the Treatment of Hashimoto Encephalopathy in Children: Two Case Reports and a Mini Review'. Together they form a unique fingerprint.

Cite this